Based on stakeholder feedback received in May 2015, CADTH has announced that in the limited instances where no Canadian patient group exists, individual patient and caregiver input will now be accepted for the CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) programs, effective immediately.
Please note that for ... Read More
06
Oct2015
31
Jul2015
Topics covered in the NEWSletter include:
Soliris Pre-Hearing Conference
New Staff Member – Legal Services
Update: Compendium of Policies, Guidelines and Procedures
Part C – Guidelines and Procedures
Schedule 9 – CPI-Adjustment Methodology
Schedule 2 – Comparable Dosage Forms
2016 HDAP Meeting Schedule & Filing Requirements:
February 29
May 2
September 12
November 28
PMPRB Transition to Canada.ca
Update: Germany Recognized Price Source
Summary ... Read More
27
Jul2015
Proposal to Amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee Act
The Ministry of Health and Long-Term Care is proposing to reform the Ontario Drug Benefit (ODB) program in order to make it more efficient, effective and sustainable.
Proposed amendments ... Read More
20
Jul2015
PDCI & H3 Survey on Private Payer Product Listing Agreements Now “Closed” for Responses
As noted in the June 24th TargetPharma, PDCI Market Access (www.pdci.ca) and H3 Consulting (www.hthree.ca) are collaborating on a survey to gauge the interest, expectations, and experience associated with private payer product listing agreements (PLAs).
Surveys ... Read More
24
Jun2015
PDCI & H3 Survey on Private Payer Product Listing Agreements Interest, Experience & Expectations
Private payers – the community of insurers, Pharmacy Benefit Managers (PBMs) and employers in Canada – are starting to build internal competencies aimed at negotiating product listing agreements (PLAs) with pharmaceutical companies. For the past several years, private ... Read More
23
Jun2015
Currently in Canada, switching and substitutability between originator biologics and biosimilars has not been established, however that is not the case internationally. Earlier this year the Dutch Medicines Evaluation Board (MEB) supported switching patients from an innovator biologic to a biosimilar, so long as health professionals are involved and the ... Read More
19
Jun2015
INESSS is offering an opportunity for in-person meetings to manufacturers who have filed a submission by the deadline for drugs to be listed on the February 2016 “Liste des médicaments". These meetings will be held between August 28 and September 11, 2015, inclusively.
Meetings will cover the following:
Discussion on clinical studies
Discussion ... Read More
12
Jun2015
The Minister of Health and Social Services has authorized three updates to the List of Medications covered by the basic prescription drug insurance plan and the List of Medications – Institutions in 2016: February 1, June 1 and October 3, 2016. Updates to the lists of medications for multisource generic ... Read More
27
May2015
The BC Ministry of Health recently wrote to manufacturers to communicate updates to its drug review process and reimbursement submission requirements.
Updates to the Drug Review Process include:
The Drug Benefit Council (DBC) will now screen drug submissions under review by CDR to determine if a full DBC review is necessary. If ... Read More
27
May2015
The Ontario Public Drug Programs Division (OPDP) recently announced amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act. The amendments include the establishment of a pricing framework for certain generic products approved for listing on the Ontario Drug Benefit (ODB) Formulary/Comparative Drug Index on or after April ... Read More